Grifols (GRFS) has announced a collaboration agreement with Google Cloud (GOOG;GOOGL) to harness its powerful technologies such as artificial intelligence to greatly accelerate the development of new Grifols biopharma medicines. AI featuring large language models will be applied across the drug-development life cycle, including identifying potential therapeutic candidates and managing clinical trial programs, to significantly reduce the time required to bring novel treatments to market. “Grifols will reinvent biopharma medicine as we know it so we can bring more treatments to more patients in more parts of the world,” said Albert Grifols Coma-Cros, Grifols Chief Scientific Innovation Officer. “Turbocharging our extensive knowledge of biopharma and plasma science with the most advanced data technologies from Google Cloud will benefit patients and society.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GRFS:
- Grifols price target raised to EUR 11.50 from EUR 10 at Barclays
- GRFS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients
- Grifols announces its Phase 4 trial of XEMBIFY met its primary endpoint
- Grifols completes enrollment in Phase 3 study of long-term Albutein